Granules India’s wholly owned subsidiary -- Granules USA has entered into an agreement with Par Pharmaceutical Inc., a subsidiary of Endo International plc, to market the generic version of OTC omeprazole and sodium bicarbonate in North America following approval by the U.S. Food and Drug Administration's, which is currently expected in July 2016.
Par Pharmaceutical's omeprazole and sodium bicarbonate is the generic equivalent of Merck/MSD Consumer Care, Inc's Zegerid OTC. Omeprazole is a proton pump inhibitor (PPI) that decreases the production of stomach acid. Sodium bicarbonate is an antacid that raises stomach pH to keep the omeprazole from breaking down in stomach acid.
Granules India is a fast growing pharmaceutical manufacturing company with world class facilities and is committed to manufacturing excellence, quality and customer service. The Company produces Finished Dosages (FDs), Pharmaceutical Formulation Intermediates (PFIs) and Active Pharmaceutical Ingredients (APIs) for quality conscious customers in the regulated and semi-regulated markets. The company's global presence extends to over 300 customers in 60 countries through offices in India, U.S., U.K., China and Colombia.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1786.05 |
Dr. Reddys Lab | 1354.20 |
Cipla | 1470.05 |
Lupin | 2190.50 |
Zydus Lifesciences | 1004.05 |
View more.. |